Global Duchenne Muscular Dystrophy (DMD) Treatment Market: Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012-2016 and Forecast 2017-2023

Veröffentlicht von: pbi
Veröffentlicht am: 13.02.2018 08:02
Rubrik: Finanzen & Versicherungen

(Presseportal openBroadcast) - Duchenne muscular dystrophy (DMD) is a genetic disorder and it is one of the 9 types of muscular dystrophy, which is characterized by progressive degeneration and weakness of muscle. It is caused due to the absence of dystrophin protein which helps to keep muscle cells intact. Onset of symptoms will be from early childhood in the age of 3-5. Guillaume Benjamin Amand Duchenne was the first French neurologist to describe about Duchenne muscular dystrophy in 1860’s.There is no known cure for duchenne muscular dystrophy but the treatment is given to control the symptoms to maximize the quality of life of the patient.
Increase in the prevalence rate of duchenne muscular dystrophy is the major factor expected to drive the market growth of Duchenne Muscular Dystrophy Treatment Market. As per, NHS estimation 100 are born with duchenne muscular dystrophy every year in the UK, while 349 new cases were reported in the U.S. in 2010 as per to Centre for Disease Control. Furthermore, Increasing in healthcare expenditure and growing awareness about Duchenne muscular dystrophy is also propelling the growth of the Duchenne Muscular Dystrophy Treatment Market. However, low treatment seeking rate because of delayed diagnosis and fast prognosis of the disorder are the factors which are restraining the growth of Duchenne muscular dystrophy.
A sample of this report is available upon request @

The Duchenne Muscular Dystrophy (DMD) Treatment Market is classified on the basis of drug class, infection type distribution channel, and geography.

Based on drug class, the Duchenne muscular dystrophy (DMD) Treatment Market is segmented into the following

• Corticosteroids
• Pain management drugs

Based on distribution channel, the Duchenne Muscular Dystrophy (DMD) Treatment Market is segmented into the following

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

To view TOC of this report is available upon request @

There are very few products are marketed for treatment of duchenne muscular dystrophy like Translama, Exondys 51 and Emflaza. Presently this market is in research phase majorly and focuses on the on-going clinical trials for the development of innovative products. Government organizations are focussing on the prevention of duchenne muscular dystrophy. For instance, world duchenne awareness day was initiated by The United Parent Projects Muscular Dystrophy (UPPMD) with the motto of raising awareness regarding duchenne muscular dystrophy globally and they have declared 07 th September as the world’s duchenne awareness day. In 2015, U.S. FDA has published a specific guidance for development of drugs to treat duchenne muscular dystrophy.

Need more information about this report @

On the basis of geographical regions, Duchenne Muscular Dystrophy (DMD) treatment market is classified as into five key regions as Europe, Asia- Pacific, North America, Middle East & Africa and Latin America. European region is the dominating market in global DMD treatment market owing to the several treatments for DMD which are approved and are under review in EU. For instance, PTC Therapeutics has recently received orphan drug designation and conditional approval for its Translarna, a gene therapy to treat DPD.

Some of the players in Duchenne muscular dystrophy (DMD) Treatment Market are Bristol-Myers Squibb(U.S), FibroGen, Inc (U.S), ITALFARMACO S.p.A. (Italy), Catabasis Pharmaceuticals, Inc.(U.S) , NS Pharma, Inc. (U.S), Marathon Pharmaceuticals, LLC (U.S), ReveraGen BioPharma, Inc. (U.S), Pfizer (U.S), Summit Therapeutics plc (U.K), Taiho Pharmaceutical Co (Japan), Sarepta Therapeutics (U.S), Inc.,Santhera Pharmaceuticals,PTC Therapeutics (Switzerland).

Get access to full summary @



Toll Free (US): +1-866-598-1553
Website @

Bitte beachten Sie, dass für den Inhalt der hier veröffentlichten Meldung nicht openBroadcast verantwortlich ist, sondern der Verfasser der jeweiligen Meldung selbst. AGB | Haftungsausschluss.